The Zika Virus: Background, Issues, and U.S. Response Considerations

Veronica Salazar (Editor)

Series: Virology Research Progress
BISAC: MED022090

Clear

$150.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

In late 2015, health officials in Brazil recognized a marked increase in the number of infants born with microcephaly (from Greek, meaning “small head”), a birth defect that may accompany significant, permanent brain damage. Although not conclusive, the increase in microcephaly is suspected to be related to the emergence of Zika virus infections in Brazil early in 2015. Zika virus is related to the viruses that cause yellow fever, dengue, West Nile, and Japanese encephalitis viruses. Historically, Zika virus was found in Africa. Since 2007, Zika transmission has also occurred in Southeast Asia and the Western Pacific. In the Americas, transmission was first identified in Brazil in May 2015. As of January 29, 2016, the Pan American Health Organization (PAHO) had received reports of local transmission in 25 countries and territories in the Americas, including Puerto Rico and the U.S. Virgin Islands. This book discusses scientific and technical aspects of Zika virus infection, including modes of transmission, symptoms, diagnosis and treatment, and prevention. Policy concerns and official actions are evolving and will also be discussed. (Imprint: Nova)

Preface

Chapter 1. Zika Virus: Basics About the Disease
Sarah A. Lister

Chapter 2. Zika Virus in Latin America and the Caribbean: U.S. Policy Considerations
Clare Ribando Seelke, Tiaji Salaam-Blyther and June S. Beittel

Chapter 3. Zika Response Funding: Request and Congressional Action
Susan B. Epstein and Sarah A. Lister

Chapter 4. Emerging Infectious Diseases: Preliminary Observations on the Zika Virus Outbreak
United States Government Accountability Office

Chapter 5. Testimony of Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Hearing on ''Examining the U.S. Public Health Response to the Zika Virus''

Chapter 6. Testimony of Joseph M. Conlon, Technical Advisor, American Mosquito Control Association. Hearing on ''Examining the U.S. Public Health Response to the Zika Virus''

Chapter 7. Statement of Dr. Luciana Borio, Acting Chief Scientist, U.S. Food and Drug Administration. Hearing on ''Examining the U.S. Public Health Response to the Zika Virus''

Chapter 8. Testimony of Dr. Thomas R. Frieden, Director, Centers for Disease Control and Prevention. Hearing on ''Examining the U.S. Public Health Response to the Zika Virus''

Chapter 9. Testimony of Lawrence O. Gostin, Faculty Director, O'Neill Institute for National and Global Health Law. Hearing on ''Examining the U.S. Public Health Response to the Zika Virus''

Chapter 10. Testimony of Dr. Kacey C. Ernst, Associate Professor, University of Arizona. Hearing on ''Science of Zika: The DNA of an Epidemic''

Chapter 11. Testimony of Dr. Daniel Neafsey, Associate Director, Genomic Center for Infectious Disease, Broad Institute of MIT and Harvard. Hearing on ''Science of Zika: The DNA of an Epidemic''

Chapter 12. Statement of Hadyn Parry, Chief Executive Officer, Oxitec. Hearing on ''Science of Zika: The DNA of an Epidemic''

Related Nova Publication

Index

You have not viewed any product yet.